Protagonist Therapeutics (PTGX) Operating Leases: 2019-2025
Historic Operating Leases for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to $8.5 million.
- Protagonist Therapeutics' Operating Leases fell 21.50% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 21.50%. This contributed to the annual value of $10.4 million for FY2024, which is N/A change from last year.
- Latest data reveals that Protagonist Therapeutics reported Operating Leases of $8.5 million as of Q3 2025, which was down 6.42% from $9.1 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Operating Leases registered a high of $11.0 million during Q2 2024, and its lowest value of $462,000 during Q1 2023.
- Over the past 3 years, Protagonist Therapeutics' median Operating Leases value was $9.8 million (recorded in 2025), while the average stood at $8.6 million.
- Data for Protagonist Therapeutics' Operating Leases shows a maximum YoY crashed of 84.91% (in 2023) over the last 5 years.
- Quarterly analysis of 5 years shows Protagonist Therapeutics' Operating Leases stood at $3.7 million in 2021, then slumped by 68.81% to $1.1 million in 2022, then plummeted by 84.91% to $462,000 in 2023, then reached $10.4 million in 2024, then decreased by 21.50% to $8.5 million in 2025.
- Its last three reported values are $8.5 million in Q3 2025, $9.1 million for Q2 2025, and $9.8 million during Q1 2025.